Drug · CHEMBL708
Comparisons in its trials39
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 39
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Ziprasidone vs Haloperidol: serious adverse events | 0 of 189 | 0 of 187 | 376 | NCT00723606 | Trial comparisons |
| Injectable vs Oral: Number of Patients Discontinuing From the Study | 81 of 153 | 80 of 152 | 305 | NCT00330863 | Trial comparisons |
| Injectable vs Oral: serious adverse events | 61 of 146 | 48 of 150 | 296 | NCT00330863 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 1 of 147 | 6 of 147 | 294 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: MADRS Response: Number of Subjects With Total MADRS Score Reduction ≥ 50 Percent From Baseline at Week 6 | 62 of 145 | 65 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: Clinical Global Impression - Improvement Scale (CGI-Improvement or CGI-I): Number of Subjects With Response (Much Improved or Very Much Improved) at Week 6 | 66 of 145 | 69 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: MADRS Remission: Number of Subjects With Total MADRS Score ≤ 12 at Week 6 | 48 of 145 | 54 of 145 | 290 | NCT00483548 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 9 of 193 | 1 of 90 | 283 | NCT00257192 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 6 of 149 | 7 of 88 | 237 | NCT00257166 | Trial comparisons |
| Stay vs Switch: serious adverse events | 0 of 102 | 2 of 117 | 219 | NCT00044655 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 0 of 80 | 1 of 125 | 205 | NCT00555997 | Trial comparisons |
| Stay vs Switch: Number Who Discontinued Medication Within First 6 Study Months | 11 of 92 | 23 of 97 | 189 | NCT00044655 | Trial comparisons |
| Ziprasidone vs Placebo: Number of Participants With Physical Examination Abnormalities | 4 of 86 | 5 of 85 | 171 | NCT02075047 | Trial comparisons |
| Ziprasidone vs Placebo: deaths from any cause | 0 of 86 | 0 of 85 | 171 | NCT02075047 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 3 of 86 | 0 of 85 | 171 | NCT02075047 | Trial comparisons |
| Ziprasidone vs Placebo: Number of Participants With Laboratory Abnormalities | 50 of 84 | 62 of 83 | 167 | NCT02075047 | Trial comparisons |
| Ziprasidone + Escitalpram vs Ziprasidone + Placebo: serious adverse events | 0 of 71 | 0 of 68 | 139 | NCT00633399 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 1 of 49 | 0 of 49 | 98 | NCT01168674 | Trial comparisons |
| Geodon Arm vs Placebo Arm: serious adverse events | 0 of 35 | 0 of 38 | 73 | NCT00490542 | Trial comparisons |
| Ziprasidone vs Sertraline/Haloperidol: serious adverse events | 1 of 35 | 0 of 37 | 72 | NCT00340379 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL708/comparisons